A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
Public ClinicalTrials.gov record NCT03928704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to demonstrate the efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared to placebo in the treatment of subjects with active nonradiographic axial spondyloarthritis (nr-axSpA).
Study identification
- NCT ID
- NCT03928704
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 274 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 25, 2019 (Actual)
- Primary completion
- Jun 29, 2022 (Actual)
- Completion
- Apr 17, 2023 (Actual)
- Last update posted
- Sep 25, 2026
2019 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| As0010 50131 | Mesa | Arizona | 85210 | — |
| As0010 50052 | Phoenix | Arizona | 85032 | — |
| As0010 50062 | Sun City | Arizona | 85351 | — |
| As0010 50060 | Upland | California | 91786 | — |
| As0010 50059 | Ormond Beach | Florida | 32174 | — |
| As0010 50056 | Sarasota | Florida | 34239 | — |
| As0010 50015 | Hagerstown | Maryland | 21740 | — |
| As0010 50016 | St Louis | Missouri | 63141 | — |
| As0010 50055 | Portland | Oregon | 97239-3011 | — |
| As0010 50020 | Duncansville | Pennsylvania | 16635 | — |
| As0010 50012 | Memphis | Tennessee | 38119-5214 | — |
| As0010 50057 | Dallas | Texas | 75231 | — |
| As0010 50036 | Mesquite | Texas | 75150 | — |
| As0010 50061 | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 69 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03928704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03928704 live on ClinicalTrials.gov.